Am Regent Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AM REGENT
AM REGENT has eighty-two approved drugs.
There are eleven US patents protecting AM REGENT drugs.
There are sixty-seven patent family members on AM REGENT drugs in thirty-two countries and two hundred and thirty-three supplementary protection certificates in sixteen countries.
Summary for Am Regent
| International Patents: | 67 |
| US Patents: | 11 |
| Tradenames: | 75 |
| Ingredients: | 72 |
| NDAs: | 82 |
Drugs and US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-004 | Feb 4, 2022 | AP | RX | Yes | Yes | 8,895,612 | ⤷ Start Trial | ⤷ Start Trial | |||
| Am Regent | FUROSEMIDE | furosemide | INJECTABLE;INJECTION | 018579-001 | Nov 30, 1983 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Am Regent | AMINOPHYLLINE | aminophylline | INJECTABLE;INJECTION | 087600-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Am Regent | BUPRENORPHINE HYDROCHLORIDE | buprenorphine hydrochloride | INJECTABLE;INJECTION | 078331-001 | Mar 27, 2007 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Am Regent | TRALEMENT | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-001 | Jul 2, 2020 | RX | Yes | Yes | 11,998,565 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-003 | Apr 28, 2021 | AP | RX | Yes | Yes | 11,433,091 | ⤷ Start Trial | ⤷ Start Trial | |||
| Am Regent | DOPAMINE HYDROCHLORIDE | dopamine hydrochloride | INJECTABLE;INJECTION | 070820-001 | Feb 11, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-004 | Feb 4, 2022 | 11,291,645 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-004 | Feb 4, 2022 | 11,590,097 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-004 | Feb 4, 2022 | 9,376,505 | ⤷ Start Trial |
| Am Regent | DEXFERRUM | iron dextran | INJECTABLE;INJECTION | 040024-001 | Feb 23, 1996 | 5,624,668 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-002 | Oct 8, 2020 | 11,123,321 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | 11,123,321 | ⤷ Start Trial |
| Am Regent | INJECTAFER | ferric carboxymaltose | SOLUTION;INTRAVENOUS | 203565-001 | Jul 25, 2013 | 10,519,252 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Am Regent Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Jordan | 3286 | ⤷ Start Trial |
| Cyprus | 1112680 | ⤷ Start Trial |
| Spain | 2385788 | ⤷ Start Trial |
| Canada | 2493806 | ⤷ Start Trial |
| South Korea | 20170028449 | ⤷ Start Trial |
| Portugal | 2287204 | ⤷ Start Trial |
| Norway | 20052410 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Am Regent Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2563920 | CA 2019 00001 | Denmark | ⤷ Start Trial | PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), ...SPECIFICALLY INOTERSEN; AND ITS DERIVATIVES, INCLUDING SODIUM SALTS ...; REG. NO/DATE: EU/1/18/1296 20180710 |
| 0454436 | SPC/GB96/058 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927 |
| 1380301 | 2009C/007 | Belgium | ⤷ Start Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| 2957286 | 300962 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721 |
| 0136011 | 2000C/027 | Belgium | ⤷ Start Trial | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 |
| 0957929 | 06C0021 | France | ⤷ Start Trial | PRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131 |
| 1453521 | C 2015 029 | Romania | ⤷ Start Trial | PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
